Bio News
Researchers used the DESynR platform to design 13,824 synthetic transcription factors that enhanced the antitumor function of CAR-T cells. The DESynR transcription factors demonstrated superior activity to natural transcription factors in vitro and in vivo. The researchers plan to apply the platform to other protein families to accelerate the development of next-generation cell therapies.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
